Journal of Endocrinological Investigation

, Volume 26, Issue 5, pp 472–480 | Cite as

Subclinical thyroid disorders: The menace of the Trojan horse

  • Leonidas H. Duntas
Review Article


This review aims at summarizing some new data regarding the so-called subclinical thyroid disease and incorporate the knowledge in order to provide a basis for a more careful approach to these morbidities. SHyper represents a considerable risk factor for atrial fibrillation in the elderly and also for osteoporosis, which is a major cause of morbidity in postmenopausal women. SHypo is not an innocuous condition. It progresses to thyroid failure in patients with positive thyroid antibodies, it affects neurobehavior, it may influence cardiac contractility at exercise and it is associated with an impaired lipid profile that may provoke atherosclerosis. Therefore, both conditions should be screened more carefully in the community and treatment should be more often considered.


Subclinical thyroid disorders thyroid 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Evered D., Hall R. Hypothyroidism. B.M.J. 1972, 1: 290–293.CrossRefGoogle Scholar
  2. 2.
    Gemsenjäger E., Staub J.J., Girard J., Heitz P.H. Preclinical hyperthyroidism in multinodular goiter. J. Clin. Endocrinol. Metab. 1976, 43: 810–816.PubMedCrossRefGoogle Scholar
  3. 3.
    Evered D.C., Ormston B.J., Smith P.A., Hall R., Bird T. Grades of hypothyroidism. B.M.J. 1973, 1: 657–662.CrossRefGoogle Scholar
  4. 4.
    Ayala A.R., Wartofsky L. The case for more aggressive screening and treatment of mild thyroid failure. Cleve. Clin. J. Med. 2002, 4: 313–320.CrossRefGoogle Scholar
  5. 5.
    Wilansky D.L., Greisman B. Early hypothyroidism in patients with menorrhagia. Am. J. Obstet. Gynecol. 1989, 160: 673–677.PubMedCrossRefGoogle Scholar
  6. 6.
    Duntas L.H. Subclinical hypothyroidism: A misnomer in search of a new name. Thyroid 2001, 11: 361–362.PubMedCrossRefGoogle Scholar
  7. 7.
    Laurberg P., Bulow-Pedersen I., Knudsen N., Oversen L., Andersen S. Environmental iodine intake affects the type of non-malignant thyroid disease. Thyroid 2001, 11: 457–469.PubMedCrossRefGoogle Scholar
  8. 8.
    Vanderpump M.P.J, Tunbridge W.M.G., French J.M., et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin. Endocrinol. (Oxf.) 1995, 43: 55–68CrossRefGoogle Scholar
  9. 9.
    Sawin C.T., Geller A., Kaplan M.M., Bacharach P., Wilson P.W.F., Hershman J.M. Low serum thyrotropin (Thyroid- Stimulating-Hormone) in older persons without hyperthyroidism. Arch. Intern. Med. 1991, 151: 165–168.PubMedCrossRefGoogle Scholar
  10. 10.
    Canaris G.J., Manowitz N.R., Mayor G., Ridgway E.C. The Colorado thyroid disease prevalence study. Arch. Intern. Med. 2000, 160: 526–534.PubMedCrossRefGoogle Scholar
  11. 11.
    Hollowell J.C., Staehling N.W., Hannon W.H., et al. Serum thyrotropin, thyroxine, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Exmination Survey (NHANES III). J. Clin. Endocrinol. Metab. 2002, 87: 489–499.PubMedCrossRefGoogle Scholar
  12. 12.
    Bartalena L., Martino F., Velluzzi M., et al. The lack of nocturnal serum thyrotropin surge in patients with nontoxic nodular goiter may predict the subsequent occurrence of hyperthyroidism. J. Clin. Endocrinol. Metab. 1991, 73: 604–608.PubMedCrossRefGoogle Scholar
  13. 13.
    Spencer C.A., Schwarzbein D., Guttler R.B., LoPresti J.S., Nicoloff J.T. Thyrotropin (TSH)-releasing hormone stimulation test responses employing third and forth generation TSH assays. J. Clin. Endocrinol. Metab. 1993, 76: 494–498.PubMedGoogle Scholar
  14. 14.
    Fatourechi V. Adverse effects of subclinical hyperthyroidism. Lancet 2001, 358: 856–857.PubMedCrossRefGoogle Scholar
  15. 15.
    Subclinical hyperthyroidism: position statement from the American Association of Clinical Endocrinologists. Endocrine Practice 1999, 5: 220–221.Google Scholar
  16. 16.
    Braverman L.E., Pearce E.N. Subclinical hyperthyroidism Thyroid International 2001, 5: 3–11.Google Scholar
  17. 17.
    Parle J.V., Franklyn J.A., Cross K.W., Jones S.C., Sheppard M.C. Prevalence and follow-up of abnormal thyrotropin (TSH) concentrations in the elderly in the United Kingdom. Clin. Endocrinol. (Oxf.) 1991, 34: 77–83.CrossRefGoogle Scholar
  18. 18.
    Schlote-Sautter B., Schmidt R., Kaumeier S., Teuber J., Vardarli I., Usaldel K.H. Subclinical hyperthyroidism: do physical and mental symptoms exist that justify treatment? In: Reinwein D. and Scriba P.C. (Eds.), The various types of hyperthyroidism. Urban & Schwartzenberg, Munich, 1990, p. 319.Google Scholar
  19. 19.
    Muente T.F., Radamm C, Soenke J., Brabant G. Alererations of cognitive functions induced by exogenous application of thyroid hormones in healthy men: a doubleblind cross-over study using event-related brain potentials. Thyroid 2001, 11: 385–391.CrossRefGoogle Scholar
  20. 20.
    Eriksen E.F. Normal and pathological remodelling of human trabecular bone: three dimensional reconstruction of the remodelling sequence in normals and in metabolic bone disease. Endocr. Rev. 1986, 7: 379–408.PubMedCrossRefGoogle Scholar
  21. 21.
    Ross D.S. Subclinical hyperthyroidism. In: Braverman L.E., Utiger R.D. (Eds.), Werner and Ingbar’s The Thyroid, ed. 6. J.B. Lippincott Company, Philadelphia, 1991, p. 1249.Google Scholar
  22. 22.
    Ross D.S., Neer R.M., Ridgway R.C., Daniels G.H. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with l-thyroxine. Am. J. Med. 1987, 82: 1167–1170.PubMedCrossRefGoogle Scholar
  23. 23.
    Grant D.J., McMurdo M.E.T., Mole P.A., Paterson C.R., Davies R.R. Suppressed TSH levels secondary to thyroxine replacement therapy are not associated with osteoporosis. Clin. Endocrinol. (Oxf.) 1993, 39: 529–533.CrossRefGoogle Scholar
  24. 24.
    Faber, J., Galloe A.M. Changes in bone mass during prolonged subclinical hyperthyroidism due to l-thyroxine treatment: a meta-analysis. Eur. J. Endocrinol. 1994, 130: 350–356.PubMedCrossRefGoogle Scholar
  25. 25.
    Marcocci C., Golia F., Vignali E., Pinchera A. Skeletal integrity in men chronically treated with suppressive doses of l-thyroxine. J. Bone Min. Res. 1997, 12: 72–77.CrossRefGoogle Scholar
  26. 26.
    Gurlek K.A., Cedik O. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 1999, 9: 539–543.PubMedCrossRefGoogle Scholar
  27. 27.
    Faber J., Jensen I.W., Petersen L., Nygaard B., Hegedus L., Siersbaek N.K. Normalization of serum thyrotropin by means of radiodine treatment in subclinical hyperthyroidism: Effect on bone loss in postmenopausal women. Clin. Endocrinol. (Oxf.) 1998, 48: 285–290.CrossRefGoogle Scholar
  28. 28.
    Guo C.Y., Weetman A.P., Eastell R. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin. Endocrinol. (Oxf.) 1997, 46: 301–307.CrossRefGoogle Scholar
  29. 29.
    Uzzan B., Campos J., Cucherat M., Nony P., Boissel J.P., Perret G.Y. Effects on bone mass of long term treatment with thyroid hormones: A meta-analysis. J. Clin. Endocrinol. Metab. 1996, 81: 4278–4289.PubMedGoogle Scholar
  30. 30.
    Bauer D.C, Ettinger B, Nevitt M.C., Stone K.L. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann. Intern. Med. 2001, 134: 561–568.PubMedCrossRefGoogle Scholar
  31. 31.
    Klein I. Thyroid hormone and the cardiovascular system. Am. J. Med. 1990, 88: 631–637.PubMedCrossRefGoogle Scholar
  32. 32.
    Klein I., Ojamaa K. Thyroid hormone and the cardiovascular system. N. Engl. J. Med. 2001, 7: 501–509Google Scholar
  33. 33.
    Mercuro G., Panzuto M..G., Bina A., et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J. Clin. Endocrinol. Metab. 2000, 85: 159–164.PubMedCrossRefGoogle Scholar
  34. 34.
    Biondi B., Palmieri E.A., Fazio S., et al. Endogenous subclinical hyperthyroidism affects quality of life, cardiac morphology and function in young and middle-aged patients. J. Clin. Endocrinol. Metab. 2000, 12: 4701–4705.Google Scholar
  35. 35.
    Sawin C.T., Geller A., Wolf P.A., et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N. Engl. J. Med. 1994, 331: 1249–1252.PubMedCrossRefGoogle Scholar
  36. 36.
    Auer J., Scheibner P., Mische T., Langsteger W., Eber O., Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am. Heart J. 2001, 142: 838–842.PubMedCrossRefGoogle Scholar
  37. 37.
    Ladenson P.W. Thyrotoxicosis and the heart: old and something new. J. Clin. Endocrinol. Metab. 1993, 77: 332–333.PubMedGoogle Scholar
  38. 38.
    Kalmijn S., Mehta K.M., Pols H.A.P., Hofman A., Drexhage H.A., Breteler M.M.B. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin. Endocrinol. (Oxf.) 2000, 53: 733–737.CrossRefGoogle Scholar
  39. 39.
    Parle J.V., Maisonneuve P., Sheppard M.C., Boyle P., Franklyn J.A. Prediction of all cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10 year cohort study. Lancet 2001, 385: 861–865.CrossRefGoogle Scholar
  40. 40.
    Shrier D.K., Burman K.D. Subclinical hyperthyroidism: controversies in management. Am. Fam. Physician 2002, 3: 431–438.Google Scholar
  41. 41.
    Levy E.G. (section editor). Subclinical hyperthyroidism. Thyroid 2000, 10: 721–723.Google Scholar
  42. 42.
    Sawin C.T. Subclinical hyperthyroidism and atrial fibrillation. Thyroid 2002, 6: 501–503.CrossRefGoogle Scholar
  43. 43.
    Tunbridge W.M., Evered D.C., Hall R., et al. Lipid profiles and cardiovascular disease in the Wickham area with particular reference to thyroid failure. Clin. Endocrinol. (Oxf.) 1977, 7: 495–508.CrossRefGoogle Scholar
  44. 44.
    Sawin C.T., Castelli W.P., Hershman J.M., Mc Namara P., Bacharach P. The aging thyroid: Thyroid deficiency in the Framingham Study. Arch. Intern. Med. 1985, 145: 1386–1388.PubMedCrossRefGoogle Scholar
  45. 45.
    Duntas L.H. Recap of the clinical use of thyrotropin-releasing hormone. In: Duntas L.H. and Guillemin R. (Eds.), Hypothalamic Releasing Hormones. Challenges and perspectives at the 2000 year mark. Beta Medical Arts, Athens, 2000, p.31.Google Scholar
  46. 46.
    Faglia G. The clinical impact of thyrotropin-releasing hormone test. Thyroid 1998, 10: 903–908.CrossRefGoogle Scholar
  47. 47.
    Michalakopoulou G., Alevizaki M., Piperingos G., et al. High serum cholesterol levels in persons with “high-normal” TSH levels: should one extend the definition of subclinical hypothyroidism? Eur. J. Endocrinol. 1998, 138: 141–145.CrossRefGoogle Scholar
  48. 48.
    Lekakis J., Papamichael C., Alevizaki M., et al. Flow-mediated endothelium dependent vasodilatation is impaired in subjects with hypothyroidism, borderline hypothyroidism and high-normal serum thyrotropin (TSH) values. Thyroid 1997, 7: 411–414.PubMedCrossRefGoogle Scholar
  49. 49.
    Cooper D.S. Subclinical hypothyroism. N. Engl. J. Med. 2001, 345: 260–265.PubMedCrossRefGoogle Scholar
  50. 50.
    Ladenson P.W., Singer P.A., Ain K.B., et al. American Thyroid Association guidelinesfor detection of thyroid dysfunction. Arch. Intern. Med. 2000, 160: 1573–1575.PubMedCrossRefGoogle Scholar
  51. 51.
    Danese M.D., Powe N.R., Sawin C.T., Ladenson P.W. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. J.A.M.A. 1996, 276: 285–292.PubMedCrossRefGoogle Scholar
  52. 52.
    Haddow J.E., Palomaki G.E., Allan W.C., et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsycho- logical development of the child. N. Engl. J. Med. 1999, 341: 549–555.PubMedCrossRefGoogle Scholar
  53. 53.
    Klein R.Z., Sargent J.D., Larsen P.R., Waisbren S.E., Haddow J.E., Mitchell M.L. Relation of severity of maternal hypothyroidism to cognitive development of offspring. J. Med. Screen. 2001, 1: 18–20.CrossRefGoogle Scholar
  54. 54.
    Davies P.H., Franklyn J.A. The effect of drugs on tests of thyroid function. Eur. J. Clin. Pharmacol. 1991, 40: 439–451.PubMedCrossRefGoogle Scholar
  55. 55.
    Asher R. Myxedematous madness. B.M.J. 1949, 22: 555–562.CrossRefGoogle Scholar
  56. 56.
    Nemeroff C.B. Subclinical hypothyroidism: a review of neuropsychiatric aspects. Int. J. Psychiatry Med. 1990, 20: 193–208.PubMedCrossRefGoogle Scholar
  57. 57.
    Haggerty J.J., Stern R.A., Mason G.A., Beckwith J., Morey C.E., Prange A.J. Jr. Prevalence of antithyroid antibodies in mood disorders. Am. J. Psychiatry 1993, 3: 508–510.Google Scholar
  58. 58.
    Berlin I., Payan C., Corruble E., Puech A.J. Serum thyroidstimulating- hormone concentration as an index of severity of major depression. Int. J. Neuropsychopharmacol. 1999, 2: 105–110.PubMedCrossRefGoogle Scholar
  59. 59.
    Nystroem E., Caidahl K., Fager G., Wikkelso C., Lundberg P.A., Lindstedt G. A double-blind cross-over 12-month study of l-thyroxine treatment of women with ‘subclinical hypothyroidism’. Clin. Endocrinol. (Oxf.) 1988, 1: 63–75.CrossRefGoogle Scholar
  60. 60.
    Monzani F., Caraccio N., Siciliano G., Manca L., Murri L., Ferannini E. Clinical and biochemical features of muscle dysfunction in subclinical hypothyroidism. J. Clin. Endocrinol. Metab. 1997, 82: 3315–3318.PubMedCrossRefGoogle Scholar
  61. 61.
    Goulis D.G., Tsimpiris N., Delaroudis S., et al. Stapedial reflex: a biologic index found to be abnormal in clinical and subclinical hypothyroidism. Thyroid 1998, 8: 583–587PubMedCrossRefGoogle Scholar
  62. 62.
    Duntas L.H., Papanastasiou L., Mantzou E., Koutras D.A. Incidence of sideropenia and effects of iron repletion treatment in women with subclinical hypothyroidism. Exp. Clin. Endocrinol. Diabetes 1999, 107: 356–360.PubMedCrossRefGoogle Scholar
  63. 63.
    Tagliaferri M., Berselli M.E., Calo G., et al. Subclinical hypothyroidism in obese patients: relation to resting energy expenditure, serum leptin, body composition and lipid profile. Obes. Res. 2001, 9: 196–201.PubMedCrossRefGoogle Scholar
  64. 64.
    Benvenga S., Robbins S. Lipoprotein-thyroid hormone interactions. Trends Endocrinol. Metab. 1996, 4: 194–198.CrossRefGoogle Scholar
  65. 65.
    Duntas L. Thyroid disease and lipids. Thyroid 2002, 12: 287–293.PubMedCrossRefGoogle Scholar
  66. 66.
    Tan K.C.B., Shiu S.W.M., Kung A.W.C. Plasma cholesteryl ester transfer protein activity in hyper-and hypothyroidism. J. Clin. Endocrinol. Metab. 1998, 83: 149–153.Google Scholar
  67. 67.
    Althaus B.U., Staub J.J., Ryff-de Leche A., Oberhaenslie A., Staehelin H.B. LDL/HDL changes in subclinical hypothyroidism: possible risk factors for coronary heart disease. Clin. Endocrinol. (Oxf.) 1988, 28: 157–163.CrossRefGoogle Scholar
  68. 68.
    Bindels A.J.G.H., Westerndorp R.G.J., Froehlich M., Seidell J.C., Blokstra A., Smelt A.H.M. The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: a need for casefinding. Clin. Endocrinol. (Oxf.) 1999, 50: 217–220.CrossRefGoogle Scholar
  69. 69.
    Bakker S.J.L., Ter Maaten J.C., Popp-Snijders C., Slaets J.P.J., Heine R.J., Gans R.O.B. The relationship between thyrotropin and low-density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J. Clin. Endocrinol. Metab. 2001, 86: 1206–1211.PubMedGoogle Scholar
  70. 70.
    Vanderpump M.P., Tunbridge W.M., French J.M., et al. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of English community. Thyroid 1996, 6:155–160.PubMedGoogle Scholar
  71. 71.
    Hak E.A., Huibert A.P., Visser T.J., Drexhage H.A., Hofman A. Witterman J.C.M. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam study. Ann. Intern. Med. 2000, 132: 270–278.PubMedCrossRefGoogle Scholar
  72. 72.
    Huber G. Staub J.J., Meier C. et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J. Cli. Endocrinol. Metab. 2002, 87: 3221–3226.CrossRefGoogle Scholar
  73. 73.
    Meier C., Staub J.J., Roth C.B., et al. TSH-controlled l-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo- contolled trial (Basel Thyroid Study). J. Clin. Endocrinol. Metab. 2001, 86: 4860–4866.PubMedCrossRefGoogle Scholar
  74. 74.
    Danese M.D., Ladenson P.W., Meinert C.L., Powe N.R. Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J. Clin. Endocrinol. Metab. 2000, 85: 2993–3001.PubMedGoogle Scholar
  75. 75.
    Tanis B.C., Westerdorp G.J., Smelt H.M. Effect of thyroid substitution on hypercholesterolemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies. Clin. Endocrinol. (Oxf.) 1996, 44: 643–649.CrossRefGoogle Scholar
  76. 76.
    Alvarez J.J, Lasuncion M.A, Olmos J.M, Herrera E. Interindividual variation in the partition of lipoprotein (a) into lipoprotein subfractions. Clin. Biochem. 1993, 26: 399–408.PubMedCrossRefGoogle Scholar
  77. 77.
    Pazos F., Alvarez J.J., Rubies-Prat J., Varela C., Lasuncion M.A. Long term thyroid hormone replacement therapy and levels of lipoprotein and other lipoproteins. J. Clin. Endocrinol. Metab. 80: 562–566.Google Scholar
  78. 78.
    Danzi S., Klein I. Thyroid hormone-regulated cardia gene expression and cardiovascular disease. Thyroid 2002, 12: 467–472.PubMedCrossRefGoogle Scholar
  79. 79.
    Kahaly G.J. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid 2000, 10: 665–679PubMedCrossRefGoogle Scholar
  80. 80.
    Arem R., Patsch W. Lipoprotein and apolipoprotein levels in subclinical hypothyroidism. Effect of levothyroxine therapy. Arch. Intern. Med. 1990, 150: 2097–2100.Google Scholar
  81. 81.
    Biondi B., Fazio S., Palmieri E.A., et al. Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J. Clin. Endocrinol. Metab. 1999, 84: 2064–2067.PubMedCrossRefGoogle Scholar
  82. 82.
    Foeldes J., Istvanfy M., Halmagyi M., Varadi A., Gara A, Partos O. Hypothyroidism and the heart examination of left ventricular function in subclinical hypothyroidism. Acta. Med. Hung. 1987, 44: 337–347.Google Scholar
  83. 83.
    Biondi B., Palmeri E.A., Lombardi G., Fazio S. Subclinical hypothyroidism and cardiac function. Thyroid 2002, 12: 505–510.PubMedCrossRefGoogle Scholar
  84. 84.
    Cooper D.S., Halpern R., Wood L.C., Levin A.A., Ridgway E.C. L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. Ann. Intern. Med. 1984, 101: 18–24.Google Scholar
  85. 85.
    Faber J., Petersen L., Winberg N., Shifter S., Mehlsen J. Hemodynamic changes after levothyroxine treatment in subclinical hypothyroidism. Thyroid 2002, 10: 319–324.CrossRefGoogle Scholar
  86. 86.
    Chu J.W., Crapo L.M. The treatment of subclinical hypothyroidism is seldom necessary. J. Clin. Endocrinol. Metab. 2001, 86: 4591–4599.PubMedCrossRefGoogle Scholar
  87. 87.
    Zulewski H., Mueller B., Exer P., Miserez A., Staub J.J. Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. J. Clin. Endocrinol. Metab. 1997, 82: 771–776.PubMedGoogle Scholar
  88. 88.
    Andersen S., Pedersen K.M., Brunn N.H., Laurberg P. Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. J. Clin. Endocrinol. Metab. 2002, 87: 1068–1072.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2003

Authors and Affiliations

  1. 1.Endocrine Unit, Evgenidion HospitalUniversity of Athens Medical SchoolAthensGreece

Personalised recommendations